Abiopharma

🔍 Krempa David (Executive)

Company: Eton Pharmaceuticals, Inc. (ETON)

Report Date: 2025-12-11

Detailed Transactions and Holdings:

• Sold 6,264 shares of Common Stock at $17.0 per share (Direct)
  Date: 2025-12-12 | Code: F | equity_swap_involved: 0 | shares_owned_after: 632,180.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 5,300 shares of Restricted Stock Units (Derivative)
  Date: 2025-12-11 | Code: A | equity_swap_involved: 0 | shares_owned_after: 638,468.00 | transaction_form_type: 4 | Footnotes: F4, F5, F5

Footnotes:

• F1: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units.
• F2: The shares were sold in multiple trades at prices ranging from $16.83 to $17.11. The price reported above reflects the weighted average sales price.
• F3: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
• F4: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.
• F5: The restricted stock units vest immediately as of the award date.
• REMARKS: The Reporting Person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.